Updated July 2026 · 8 min read

Procainamide: The ICU Nurse's Guide

Part of the ICU Emergencies Hub — browse every related guide in one place.

Procainamide is the antiarrhythmic you load slowly with your eyes on the QRS. It is a first-line option for stable wide-complex tachycardia and one of the few safe choices for pre-excited atrial fibrillation, but it comes with hard, watch-them-live stopping rules. Here is how to run it without getting surprised.

How procainamide works

Procainamide slows conduction by blocking fast sodium channels (a class Ia effect), which widens the QRS, and it also blocks potassium channels, which prolongs repolarization and lengthens the QT. That dual action makes it effective across a wide range of atrial and ventricular arrhythmias, including accessory-pathway rhythms where AV-nodal blockers are dangerous. The same channel effects are why the ECG itself — QRS width and QT — becomes your dosing gauge.

Dosing and the four stop points

The defining feature of a procainamide load is that you stop it the moment any of four things happens: the arrhythmia converts, the QRS widens by more than 50% of baseline, blood pressure drops, or you hit the maximum dose. Because you can reach any of these mid-infusion, procainamide is loaded slowly with a continuous ECG and frequent blood-pressure checks, not hung and walked away from.

Side effects and toxicity

Hypotension is the acute dose-limiter, driven by vasodilation and negative inotropy, and it worsens with faster loading — another reason the load is deliberate.

QT prolongation and torsades. The potassium-channel block that prolongs repolarization can trigger polymorphic VT, so procainamide is avoided when the baseline QT is already long or in known long-QT patients.

NAPA accumulation. Procainamide is metabolized to N-acetylprocainamide, an active metabolite cleared by the kidneys. In renal impairment NAPA builds up and adds its own QT-prolonging toxicity, so both drug and metabolite levels matter in those patients.

Drug-induced lupus. With prolonged therapy, procainamide can cause a reversible lupus-like syndrome — arthralgias, fever, positive ANA. It is a chronic-use concern rather than an acute-drip one, but worth knowing when a patient stays on it.

Where it fits

Procainamide shines in two spots: stable monomorphic ventricular tachycardia with a pulse, where guidelines favor it, and pre-excited (WPW) atrial fibrillation, where AV-nodal agents like diltiazem, adenosine, and beta-blockers can accelerate conduction down the accessory pathway and are contraindicated. In an unstable patient, electricity — not procainamide — is the answer.

Why CRNA students should know it

On the CRNA path, the perioperative period is full of arrhythmias, and understanding a class Ia agent's QRS/QT footprint, its use in accessory-pathway rhythms, and its hypotension risk builds the electrophysiology fluency anesthesia demands. Recognizing when a wide-complex tachycardia needs procainamide versus cardioversion is exactly the judgment tested in critical care and the OR.

Bottom line

Procainamide is the deliberate, ECG-guided antiarrhythmic for stable wide-complex tachycardia and pre-excited AF: load slowly, stop on conversion, QRS widening, hypotension, or max dose, and dose down for renal failure because of NAPA. Never use it as a substitute for cardioversion in an unstable patient. Master the four stop points now.

This article is general educational information for licensed clinicians and students, not medical advice or a substitute for your institution's protocols, pharmacy guidance, or a provider's orders. Always follow facility policy and verify every dose independently.